Dendreon Overview

  • Year Founded
  • 1992

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 710

Employees

  • Latest Deal Type
  • Debt - PPP

  • Latest Deal Amount
  • $10M

Dendreon General Information

Description

Operator of a biopharmaceutical company intended to offer manufacturing services for the cell therapy market. The company engages in the discovery, development, commercialization, and manufacturing of immunotherapy product candidates and offers products that reprogram the body's immune cells to detect and attack cancer cells, with little impact on healthy tissue or cells, enabling medical practitioners to help extend the lives of patients battling cancer.

Contact Information

Website
www.dendreon.com
Formerly Known As
Activated Cell Therapy
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • 1700 Saturn Way
  • Seal Beach, CA 90740
  • United States
+1 (877)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Parent Company
Nanjing Xinjiekou Department Store Company
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 1700 Saturn Way
  • Seal Beach, CA 90740
  • United States
+1 (877)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Dendreon Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
19. Debt - PPP 14-Apr-2020 $10M Completed Generating Revenue
18. Debt - General 14-Apr-2020 Completed Generating Revenue
17. Merger/Acquisition 03-Aug-2018 Completed Generating Revenue
16. Merger/Acquisition 29-Jun-2017 Completed Generating Revenue
15. Merger/Acquisition 23-Feb-2015 Completed Generating Revenue
14. Bankruptcy: Admin/Reorg 10-Nov-2014 Completed Bankruptcy: Admin/Reorg
13. Merger/Acquisition 25-Oct-2013 Cancelled Generating Revenue
12. 2PO 11-Dec-2009 Completed Generating Revenue
11. PIPE 13-May-2009 $221M $548M Completed Generating Revenue
10. PIPE 03-Apr-2008 $46M $327M Completed Generating Revenue
To view Dendreon’s complete valuation and funding history, request access »

Dendreon Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a biopharmaceutical company intended to offer manufacturing services for the cell therapy market. The compan
Biotechnology
Seal Beach, CA
710 As of 2014

Gaithersburg, MD
 

Santa Monica, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Dendreon Competitors (57)

One of Dendreon’s 57 competitors is NexImmune, a Formerly VC-backed company based in Gaithersburg, MD.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
NexImmune Formerly VC-backed Gaithersburg, MD
Kite Pharma Formerly VC-backed Santa Monica, CA
Sorrento Therapeutics Formerly VC-backed San Diego, CA
Gadeta Formerly VC-backed Utrecht, Netherlands
Aurora Biopharma Angel-Backed Cambridge, MA
You’re viewing 5 of 57 competitors. Get the full list »

Dendreon Patents

  • 628

    Total Documents Applications and Grants

  • Total Patents Families

  • 187

    Granted

  • 12

    Pending

  • Expiring in next 12 mo

Dendreon Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20200017921-A1 Gene expression markers for predicting overall survival in subjects treated with sipuleucel-t Active 15-Oct-2015
US-20170107580-A1 Gene expression markers for predicting overall survival in subjects treated with sipuleucel-t Inactive 15-Oct-2015
US-11970743-B2 Gene expression markers for predicting overall survival in subjects treated with sipuleucel-t Active 15-Oct-2015
CA-2923433-A1 Humoral immune response against tumor antigens after treatment with a cancer antigen specific active immunotherapy and its association with improved clinical outcome Active 05-Sep-2013
CA-2923433-C Humoral immune response against tumor antigens after treatment with a cancer antigen specific active immunotherapy and its association with improved clinical outcome Active 05-Sep-2013 G01N33/6854
To view Dendreon’s complete patent history, request access »

Dendreon Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Dendreon Former Investors (16)

Investor Name Investor Type Holding Investor Since Participating Rounds
Alliance of Angels Angel Group Minority
Azimuth Opportunity Investment Bank Minority
Bausch Health Companies Corporation Majority
Angel (individual) Minority
Cercano Management PE/Buyout Minority
You’re viewing 5 of 16 investors. Get the full list »

Dendreon Acquisitions (1)

Dendreon’s most recent deal was a Merger/Acquisition with Corvas for . The deal was made on 30-Jul-2003.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Corvas 30-Jul-2003 Merger/Acquisition Biotechnology
To view Dendreon’s complete acquisitions history, request access »

Ready to get started?

Request a free trial

Dendreon FAQs

  • When was Dendreon founded?

    Dendreon was founded in 1992.

  • Where is Dendreon headquartered?

    Dendreon is headquartered in Seal Beach, CA.

  • What is the size of Dendreon?

    Dendreon has 710 total employees.

  • What industry is Dendreon in?

    Dendreon’s primary industry is Biotechnology.

  • Is Dendreon a private or public company?

    Dendreon is a Private company.

  • What is Dendreon’s current revenue?

    The current revenue for Dendreon is .

  • How much funding has Dendreon raised over time?

    Dendreon has raised $7.5M.

  • Who are Dendreon’s investors?

    Alliance of Angels, Azimuth Opportunity, Bausch Health Companies, , and Cercano Management are 5 of 16 investors who have invested in Dendreon.

  • Who are Dendreon’s competitors?

    NexImmune, Kite Pharma, Sorrento Therapeutics, Gadeta, and Aurora Biopharma are some of the 57 competitors of Dendreon.

  • When was Dendreon acquired?

    Dendreon was acquired on 14-Apr-2020.

  • Who acquired Dendreon?

    Dendreon was acquired by Nanjing Xinjiekou Department Store Company.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »